Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets

Journal of Virology

Volumn 88, Issue 6, 2014, Pages 3432-3442

  Krammer, Florian ^a   Hai, Rong ^a   Yondola, Mark ^a,c   Tan, Gene S ^a   Leyva Grado, Victor H ^a   Ryder, Alex B ^b   Miller, Matthew S ^a   Rose, John K ^b   Palese, Peter ^a   García Sastre, Adolfo ^a   Albrecht, Randy A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Avatar Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 6F12; STALK REACTIVE MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FERRET; IMMUNE RESPONSE; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; LUNG; MALE; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; PROTEIN DOMAIN; TURBINATE; VIRUS IMMUNITY; VIRUS LOAD;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FERRETS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HEMAGGLUTININS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PROTEIN STRUCTURE, TERTIARY;

EID: 84896720073     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03004-13     Document Type: Article

References (74)

1. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. 2007. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25:5086-5096. http://dx.doi.org/10.1016/j.vaccine.2007.03.046.
2. Centers for Disease Control and Prevention. 2010. Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR Morb. Mortal. Wkly. Rep. 59:1057-1062. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5933a1.htm.
3. Centers for Disease Control and Prevention. 2011. Interim results: state-specific influenza vaccination coverage-United States, August 2010-February 2011. MMWR Morb. Mortal. Wkly. Rep. 60:737-743. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6022a3.htm.
4. Williams WW, Lu PJ, Lindley MC, Kennedy ED, Singleton JA, Centers for Disease Control and Prevention. 2012. Influenza vaccination coverage among adults-National Health Interview Survey, United States, 2008-09 influenza season. MMWR Morb. Mortal. Wkly. Rep. 61(Suppl): 65-72. http://www.cdc.gov/mmwr/preview/mmwrhtml/su6102a11.htm.
5. Wang TT, Palese P. 2011. Biochemistry. Catching a moving target. Science 333:834-835. http://dx.doi.org/10.1126/science.1210724.
6. Centers for Disease Control and Prevention. 2009. Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb. Mortal. Wkly. Rep. 58:400-402. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5815a5.htm.
7. Centers for Disease Control and Prevention. 2009. Update on influenza A (H1N1) 2009 monovalent vaccines.MMWRMorb. Mortal. Wkly. Rep. 58:1100-1101. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm583 9a3.htm.
8. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, Yuan Z, Shu Y. 2013. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 368:1888-1897. http://dx.doi.org/10.1056/NEJMoa1304459.
9. Centers for Disease Control and Prevention. 2012. Notes from the field: highly pathogenic avian influenzaA(H7N3) virus infection in two poultry workers-Jalisco, Mexico, July 2012. MMWR Morb. Mortal. Wkly. Rep. 61:726-727. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6136a 4.htm.
10. Kayali G, Barbour E, Dbaibo G, Tabet C, Saade M, Shaib HA, Debeauchamp J, Webby RJ. 2011. Evidence of infection with H4 and H11 avian influenza viruses among Lebanese chicken growers. PLoS One 6:e26818. http://dx.doi.org/10.1371/journal.pone.0026818.
11. Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, Meijer A, van Steenbergen J, Fouchier R, Osterhaus A, Bosman A. 2004. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363:587-593. http://dx.doi.org/10.1016/S0140-6736 (04)15589-X.
12. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, Orr WK, Shortridge KF. 1999. Human infection with influenza H9N2. Lancet 354: 916-917. http://dx.doi.org/10.1016/S0140-6736(99)03311-5.
13. Tweed SA, Skowronski DM, David ST, Larder A, Petric M, Lees W, Li Y, Katz J, Krajden M, Tellier R, Halpert C, Hirst M, Astell C, Lawrence D, Mak A. 2004. Human illness from avian influenza H7N3, British Columbia. Emerg. Infect. Dis. 10:2196-2199. http://dx.doi.org/10.3201/eid1012.040961.
14. Yuan J, Zhang L, Kan X, Jiang L, Yang J, Guo Z, Ren Q. 2013. Origin and molecular characteristics of a novel 2013 avian influenza A(H6N1) virus causing human infection in Taiwan. Clin. Infect. Dis. 57:1367-1368. http://dx.doi.org/10.1093/cid/cit479.
15. Bommakanti G, Citron MP, Hepler RW, Callahan C, Heidecker GJ, Najar TA, Lu X, Joyce JG, Shiver JW, Casimiro DR, ter Meulen J, Liang X, Varadarajan R. 2010. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl. Acad. Sci. U.S.A. 107:13701-13706. http://dx.doi.org/10.1073/pnas.1007465107.
16. Sagawa H, Ohshima A, Kato I, Okuno Y, Isegawa Y. 1996. The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J. Gen. Virol. 77(Pt 7):1483-1487. http://dx.doi.org/10.1099/0022-1317-77-7-1483.
17. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, Garcia-Sastre A, Palese P. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1:e00018-10. http://dx.doi.org/10.1128/mBio.00018-10.
18. Goff PH, Eggink D, Seibert CW, Hai R, Martínez-Gil L, Krammer F, Palese P. 2013. Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One 8:e79194. http://dx.doi.org/10.1371/journal.pone.0079194.
19. Hai R, Krammer F, Tan GS, Pica N, Eggink D, Maamary J, Margine I, Albrecht RA, Palese P. 2012. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J. Virol. 86:5774-5781. http://dx.doi.org/10.1128/JVI.00137-12.
20. Krammer F, Margine I, Tan GS, Pica N, Krause JC, Palese P. 2012. A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS One 7:e43603. http://dx.doi.org/10.1371/journal.pone.0043603.
21. Krammer F, Pica N, Hai R, Margine I, Palese P. 2013. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87:6542-6550. http://dx.doi.org/10.1128/JVI.00641-13.
22. Margine I, Krammer F, Hai R, Heaton NS, Tan GS, Andrews SA, Runstadler JA, Wilson PC, Albrecht RA, Garcia-Sastre A, Palese P. 2013. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J. Virol. 87:10435-10446. http://dx.doi.org/10.1128/JVI.01715-13.
23. Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, Wilson IA, Garcia-Sastre A, Moran TM, Palese P. 2010. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. U.S.A. 107:18979-18984. http://dx.doi.org/10.1073/pnas.1013387107.
24. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, Andersen H, Rao S, Tumpey TM, Yang ZY, Nabel GJ. 2010. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329:1060-1064. http://dx.doi.org/10.1126/science.1192517.
25. Wei CJ, Yassine HM, McTamney PM, Gall JG, Whittle JR, Boyington JC, Nabel GJ. 2012. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci. Transl. Med. 4:147ra114. http://dx.doi.org/10.1126/scitranslmed.3004273.
26. Kanekiyo M, Wei CJ, Yassine HM, McTamney PM, Boyington JC, Whittle JR, Rao SS, Kong WP, Wang L, Nabel GJ. 2013. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499:102-106. http://dx.doi.org/10.1038/nature12202.
27. Krammer F, Palese P. 2013. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. 3:521-530. http://dx.doi.org/10.1016/j.coviro.2013.07.007.
28. Krammer F, Palese P. 2013. Universal influenza virus vaccines: need for clinical trials. Nat. Immunol. 15:3-5. http://dx.doi.org/10.1038/ni.2761.
29. Corti D, Suguitan AL, Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120:1663-1673. http://dx.doi.org/10.1172/JCI41902.
30. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Brakenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmit J. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333:843-850. http://dx.doi.org/10.1126/science.1204839.
31. Krammer F, Pica N, Hai R, Tan GS, Palese P. 2012. Hemagglutinin stalk-reactive antibodies are boosted following sequential infection with seasonal and pandemic H1N1 influenza virus in mice. J. Virol. 86:10302-10307. http://dx.doi.org/10.1128/JVI.01336-12.
32. Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, Lee JH, Huang M, Qu X, Edupuganti S, Mulligan M, Das SR, Yewdell JW, Mehta AK, Wilson PC, Ahmed R. 2012. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-eactive memory B cells. Proc. Natl. Acad. Sci. U.S.A. 109:9047-9052. http://dx.doi.org/10.1073/pnas.1118979109.
33. Miller MS, Gardner TJ, Krammer F, Aguado LC, Tortorella D, Basler CF, Palese P. 2013. Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci. Transl. Med. 5:198ra107. http://dx.doi.org/10.1126/scitranslmed.3006637.
34. Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, Palese P. 2013. 1976 and 2009 H1N1 influenza virus vaccines boost antihemagglutinin stalk antibodies in humans. J. Infect. Dis. 207:98-105. http://dx.doi.org/10.1093/infdis/jis652.
35. Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR, Banach D, Wrammert J, Belshe RB, García-Sastre A, Palese P. 2012. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc. Natl. Acad. Sci. U.S.A. 109:2573-2578. http://dx.doi.org/10.1073/pnas.1200039109.
36. Thomson CA, Wang Y, Jackson LM, Olson M, Wang W, Liavonchanka A, Keleta L, Silva V, Diederich S, Jones RB, Gubbay J, Pasick J, Petric M, Jean F, Allen VG, Brown EG, Rini JM, Schrader JW. 2012. Pandemic H1N1 influenza infection and vaccination in humans induces crossprotective antibodies that target the hemagglutinin stem. Front. Immunol. 3:87. http://dx.doi.org/10.3389/fimmu.2012.00087.
37. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208:181-193. http://dx.doi.org/10.1084/jem.20101352.
38. Schnell MJ, Buonocore L, Whitt MA, Rose JK. 1996. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J. Virol. 70:2318-2323.
39. Lawson ND, Stillman EA, Whitt MA, Rose JK. 1995. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. U.S.A. 92:4477-4481. http://dx.doi.org/10.1073/pnas.92.10.4477.
40. Fuerst TR, Niles EG, Studier FW, Moss B. 1986. Eukaryotic transientexpression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. U.S.A. 83: 8122-8126. http://dx.doi.org/10.1073/pnas.83.21.8122.
41. Evans JD, Hearing P. 2003. Distinct roles of the adenovirus E4 ORF3 protein in viral DNA replication and inhibition of genome concatenation. J. Virol. 77:5295-5304. http://dx.doi.org/10.1128/JVI.77.9.5295-5304.2003.
42. Schmid SI, Hearing P. 1999. Adenovirus DNA packaging, p 47-59. In Wold WSM (ed), Adenovirus methods and protocols. Humana Press, Totowa, NJ.
43. Tan GS, Krammer F, Eggink D, Kongchanagul A, Moran TM, Palese P. 2012. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J. Virol. 86:6179-6188. http://dx.doi.org/10.1128/JVI.00469-12.
44. Moran T, Liu YC, Schulman JL, Bona CA. 1984. Shared idiotopes among monoclonal antibodies specific for A/PR/8/34 (H1N1) and X-31(H3N2) influenza viruses. Proc. Natl. Acad. Sci. U.S.A. 81:1809-1812. http://dx.doi.org/10.1073/pnas.81.6.1809.
45. Margine I, Palese P, Krammer F. 2013. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 Influenza virus using the baculovirus expression system. J. Vis. Exp. 81: e51112. http://dx.doi.org/10.3791/51112.
46. Baker SF, Guo H, Albrecht RA, Garcia-Sastre A, Topham DJ, Martínez-Sobrido L. 2013. Protection against lethal influenza with a viral mimic. J. Virol. 87:8591-8605. http://dx.doi.org/10.1128/JVI.01081-13.
47. Martínez-Romero C, de Vries E, Belicha-Villanueva A, Mena I, Tscherne DM, Gillespie VL, Albrecht RA, de Haan CA, Garcia-Sastre A. 2013. Substitutions T200A and E227A in the hemagglutinin of pandemic 2009 influenza A virus increase lethality but decrease transmission. J. Virol. 87:6507-6511. http://dx.doi.org/10.1128/JVI.00262-13.
48. Seibert CW, Kaminski M, Philipp J, Rubbenstroth D, Albrecht RA, Schwalm F, Stertz S, Medina RA, Kochs G, Garcia-Sastre A, Staeheli P, Palese P. 2010. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J. Virol. 84:11219-11226. http://dx.doi.org/10.1128/JVI.01424-10.
49. Seibert CW, Rahmat S, Krause JC, Eggink D, Albrecht RA, Goff PH, Krammer F, Duty JA, Bouvier NM, Garcia-Sastre A, Palese P. 2013. Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs. J. Virol. 87:7793-7804. http://dx.doi.org/10.1128/JVI.00979-13.
50. Zhu Z, Bossart KN, Bishop KA, Crameri G, Dimitrov AS, McEachern JA, Feng Y, Middleton D, Wang LF, Broder CC, Dimitrov DS. 2008. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J. Infect. Dis. 197:846-853. http://dx.doi.org/10.1086/528801.
51. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin Ö, Sieuwerts M, Brakenhoff JP, Vogels R, Li OT, Poon LL, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH. 2012. Highly conserved protective epitopes on influenza B viruses. Science 337:1343-1348. http://dx.doi.org/10.1126/science.1222908.
52. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246-251. http://dx.doi.org/10.1126/science.1171491.
53. Heaton NS, Leyva-Grado VH, Tan GS, Eggink D, Hai R, Palese P. 2013. In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies. J. Virol. 87: 8272-8281. http://dx.doi.org/10.1128/JVI.00969-13.
54. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16:265-273. http://dx.doi.org/10.1038/nsmb.1566.
55. + memory B cells. PLoS One 3:e3942. http://dx.doi.org/10.1371/journal.pone.0003942.
56. Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, Palese P. 2010. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 6:e1000796. http://dx.doi.org/10.1371/journal.ppat.1000796.
57. DeVries A, Wotton J, Lees C, Boxrud D, Uyeki T, Lynfield R. 2012. Neuraminidase H275Y and hemagglutinin D222G mutations in a fatal case of 2009 pandemic influenza A (H1N1) virus infection. Influenza Other Respir. Viruses 6:e85-8. http://dx.doi.org/10.1111/j.1750-2659.2011.00329.x.
58. Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, Zhang X, Yen HL, Shi B, Li T, Guan W, Xu L, Liu Y, Wang S, Tian D, Zhu Z, He J, Huang K, Chen H, Zheng L, Li X, Ping J, Kang B, Xi X, Zha L, Li Y, Zhang Z, Peiris M, Yuan Z. 2013. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381:2273-2279. http://dx.doi.org/10.1016/S0140-6736(13)61125-3.
59. Hurt AC, Leang SK, Tiedemann K, Butler J, Mechinaud F, Kelso A, Downie P, Barr IG. 2013. Progressive emergence of an oseltamivirresistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient. Influenza Other Respir. Viruses 7:904-908. http://dx.doi.org/10.1111/irv.12108.
60. Iioka F, Sada R, Maesako Y, Nakamura F, Ohno H. 2012. Outbreak of pandemic 2009 influenza A/H1N1 infection in the hematology ward: fatal clinical outcome of hematopoietic stem cell transplant recipients and emergence of the H275Y neuraminidase mutation. Int. J. Hematol. 96: 364-369. http://dx.doi.org/10.1007/s12185-012-1139-1.
61. Shetty AK, Ross GA, Pranikoff T, Gubareva LV, Sechrist C, Guirand DM, Abramson J, Lin JJ. 2012. Oseltamivir-resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient. Pediatr. Transplant. 16:E153-E157. http://dx.doi.org/10.1111/j.1399-3046.2011.01489.x.
62. van der Vries E, Stittelaar KJ, van Amerongen G, Veldhuis Kroeze EJ, de Waal L, Fraaij PL, Meesters RJ, Luider TM, van der Nagel B, Koch B, Vulto AG, Schutten M, Osterhaus AD. 2013. Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets. PLoS Pathog. 9:e1003343. http://dx.doi.org/10.1371/journal.ppat.1003343.
63. van Kampen JJ, Bielefeld-Buss AJ, Ott A, Maaskant J, Faber HJ, Lutisan G, Boucher CA. 2013. Case report: oseltamivir-induced resistant pandemic influenza A (H1N1) virus infection in a patient with AIDS and Pneumocystis jirovecii pneumonia. J. Med. Virol. 85:941-943. http://dx.doi.org/10.1002/jmv.23560.
64. Sangster MY, Baer J, Santiago FW, Fitzgerald T, Ilyushina NA, Sundararajan A, Henn AD, Krammer F, Yang H, Luke CJ, Zand MS, Wright PF, Treanor JJ, Topham DJ, Subbarao K. 2013. The B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza vaccination. Clin. Vaccine Immunol. 20: 867-876. http://dx.doi.org/10.1128/CVI.00735-12.
65. Ellebedy AH, Fabrizio TP, Kayali G, Oguin TH, Brown SA, Rehg J, Thomas PG, Webby RJ. 2010. Contemporary seasonal influenza A (H1N1) virus infection primes for a more robust response to split inactivated pandemic influenza A (H1N1) virus vaccination in ferrets. Clin. Vaccine Immunol. 17:1998-2006. http://dx.doi.org/10.1128/CVI.00247-10.
66. Hossain MJ, Bourgeois M, Quan FS, Lipatov AS, Song JM, Chen LM, Compans RW, York I, Kang SM, Donis RO. 2011. Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza. Clin. Vaccine Immunol. 18:2010-2017. http://dx.doi.org/10.1128/CVI.05206-11.
67. Baras B, de Waal L, Stittelaar KJ, Jacob V, Giannini S, Kroeze EJ, van den Brand JM, van Amerongen G, Simon JH, Hanon E, Mossman SP, Osterhaus AD. 2011. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets. Vaccine 29:2120-2126. http://dx.doi.org/10.1016/j.vaccine.2010.12.125.
68. Kreijtz JH, Süzer Y, Bodewes R, Schwantes A, van Amerongen G, Verburgh RJ, de Mutsert G, van den Brand J, van Trierum SE, Kuiken T, Fouchier RA, Osterhaus AD, Sutter G, Rimmelzwaan GF. 2010. Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J. Gen. Virol. 91:2745-2752. http://dx.doi.org/10.1099/vir.0.024885-0.
69. Kilbourne ED, Cerini CP, Khan MW, Mitchell JW, Ogra PL. 1987. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J. Immunol. 138:3010-3013.
70. Palese P, Wang TT. 2011. Why do influenza virus subtypes die out? A hypothesis. mBio 2:e00150-11. http://dx.doi.org/10.1128/mBio.00150-11.
71. Bodewes R, Kreijtz JH, van Amerongen G, Hillaire ML, Vogelzang-van Trierum SE, Nieuwkoop NJ, van Run P, Kuiken T, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. 2013. Infection of the upper respiratory tract with seasonal influenza A(H3N2) virus induces protective immunity in ferrets against infection with A(H1N1)pdm09 virus after intranasal, but not intratracheal, inoculation. J. Virol. 87:4293-4301. http://dx.doi.org/10.1128/JVI.02536-12.
72. Hillaire ML, van Trierum SE, Kreijtz JH, Bodewes R, Geelhoed-Mieras MM, Nieuwkoop NJ, Fouchier RA, Kuiken T, Osterhaus AD, Rimmelzwaan GF. 2011. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J. Gen. Virol. 92:2339-2349. http://dx.doi.org/10.1099/vir.0.033076-0.
73. Kreijtz JH, Bodewes R, van den Brand JM, de Mutsert G, Baas C, van Amerongen G, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. 2009. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 27:4983-4989. http://dx.doi.org/10.1016/j.vaccine.2009.05.079.
74. + T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18:274-280. http://dx.doi.org/10.1038/nm.2612.